DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • Hong Kong
  • /
  • Healthcare
Author Program NEWCreate Narrative
1099 logo

Sinopharm Group Co. Ltd. Stock Price

SEHK:1099 Community·HK$46.9b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 17 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

1099 Share Price Performance

HK$15.03
-3.81 (-20.22%)
​
HK$16.50
Fair Value
HK$15.03
-3.81 (-20.22%)
8.9% undervalued intrinsic discount
HK$16.50
Fair Value
Price HK$15.03
kapirey HK$16.50
Tue, 26 May 26
Fair ValueHK$16.50
Share Pricen/a

1099 Community Narratives

KA
kapirey
kapirey's
Fair Value
·
Fair Value HK$16.5 8.9% undervalued intrinsic discount

value + defensive emerging markets healthcare

0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
1099 logo
Sinopharm Group
8.9% undervalued intrinsic discount

value + defensive emerging markets healthcare

View narrative
KA
kapirey
kapirey
Updated 26 May
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

KA
kapirey
1099 logo

value + defensive emerging markets healthcare

Fair Value: HK$16.5 8.9% undervalued intrinsic discount
4 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Very undervalued with flawless balance sheet and pays a dividend.

1 Risk
5 Rewards
View Full Analysis

Sinopharm Group Co. Ltd. Key Details

CN¥571.9b

Revenue

CN¥531.5b

Cost of Revenue

CN¥40.4b

Gross Profit

CN¥33.3b

Other Expenses

CN¥7.1b

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
2.27
7.06%
1.24%
57.0%
View Full Analysis

About 1099

Founded
2003
Employees
90447
CEO
Wanyong Lian
WebsiteView website
www.sinopharmgroup.com.cn

Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and healthcare products, and medical devices in the People’s Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices Distribution, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical products to hospitals, other distributors, retail pharmacy stores, and clinics. This segment also offers distribution, logistics, and other value-added services for domestic and international pharmaceutical and healthcare products manufacturers, and other suppliers. The Medical Devices Distribution segment distributes medical devices, as well as provides installation and maintenance services. The Retail Pharmacy segment operates and franchises a network of retail drug stores. The Other Business segment engages in the distribution of laboratory supplies; manufacture and distribution of chemical reagents; and production and sale of pharmaceutical products. The company rents and manages properties; distributes medical instruments and equipment, Chinese herbal medicines, antibiotics, and biological products; and offers information technology, investment, goods and technology import and export, business consulting, health consultation, medical consulting, market information consulting and investigation, and convention and exhibition services. It also manages medical project investment, consulting, and technology training activities; and manufactures medicines. Sinopharm Group Co. Ltd. was founded in 2003 and is headquartered in Shanghai, the People’s Republic of China. Sinopharm Group Co. Ltd. is a subsidiary of Sinopharm Industrial Investment Co., Ltd.

Recent 1099 News & Updates

Analysis Article • Aug 27

Analysts Have Been Trimming Their Sinopharm Group Co. Ltd. (HKG:1099) Price Target After Its Latest Report

Shareholders might have noticed that Sinopharm Group Co. Ltd. ( HKG:1099 ) filed its interim result this time last...

Recent updates

No updates

Sinopharm Group Co. Ltd. Competitors

2526 logo

Hangzhou Diagens Biotechnology

Symbol: SEHK:2526
Market cap: HK$36.3b
2252 logo

Shanghai MicroPort MedBot (Group)

Symbol: SEHK:2252
Market cap: HK$21.8b
2276 logo

Shanghai Conant Optical

Symbol: SEHK:2276
Market cap: HK$19.7b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide